MedTrace Logo

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

NCT05030519 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-03-02

No results posted yet for this study

Summary

By measuring the intestinal flora abundance and bacterial count of patients in the early stage of using pyrotinib to clarify the relationship between diarrhea caused by pyrotinib and changes in intestinal flora in breast cancer patients, the correlation between the change of intestinal flora and the relief of diarrhea are also explored after two-cycle treatment.

Conditions

Interventions

DRUG

Pyrotinib

Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Wenming Cao, Ph.D. · Department of Breast Medical Oncology, Zhejiang Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2022-06-30
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05030519 on ClinicalTrials.gov